2018 Controlled Substances Hospitals 
FDA Law Blog: Biosimilars
MAY 16, 2024
Houck — Employee diversion of controlled substances from hospitals has been an issue since at least 1986 when I became a diversion investigator with the Drug Enforcement Administration (“DEA”). DEA alleged that UMHS failed to maintain complete and accurate records and failed to timely notify DEA of controlled substance thefts.
The Nontraditional Pharmacist
AUGUST 19, 2019
So I recently graduated in May of 2018 from VCU School of Pharmacy in Virginia and I work for a company called Kit Check, which is a Health I.T. So in hospitals the current methods of drug diversion detection is a really manual process which requires a lot of sifting through large volumes of data from different systems.
FDA Law Blog: Biosimilars
FEBRUARY 27, 2024
2018) , Arnold Partnership v. The PTO’s not-even-specious-argument, citing what certainly appears to us to be absolutely irrelevant case law, such as Novartis AG v. Ezra Ventures LLC, 909 F.3d 3d 1367 (Fed. Rogan , 246 F. 2d 460 (E.D. 2003) , and Biogen lnt’l v. Banner Life Sciences LLC, 956 F.3d 3d 1351 (Fed. Patent Nos.
Expert insights. Personalized for you.
59 
Let's personalize your content